Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay

Standard Number GTA-14
Organization Nanotechnology Characterization Laboratory USA
Level National
Category Specification
  • JAN 2011 Published
This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade (1, 2). The protocol utilizes a fluorescent method to measure Caspase-3/7 activation. This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).